Capricor Therapeutics Target of Unusually High Options Trading (NASDAQ:CAPR)

Capricor Therapeutics Inc (NASDAQ:CAPR) was the target of unusually large options trading on Thursday. Stock traders acquired 11,316 call options on the company. This represents an increase of approximately 214% compared to the typical daily volume of 3,599 call options.

Hedge Funds Weigh In On Capricor Therapeutics

Large investors have recently modified their holdings of the company. Summit Investment Advisors Inc. increased its position in Capricor Therapeutics by 54.1% during the 4th quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company’s stock valued at $53,000 after purchasing an additional 1,345 shares during the period. Russell Investments Group Ltd. lifted its holdings in Capricor Therapeutics by 172.8% in the fourth quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company’s stock valued at $64,000 after acquiring an additional 2,947 shares during the period. Virtus ETF Advisers LLC purchased a new stake in shares of Capricor Therapeutics in the 4th quarter worth $68,000. AlphaQuest LLC purchased a new position in Capricor Therapeutics during the fourth quarter valued at approximately $78,000. Finally, New York State Common Retirement Fund boosted its holdings in Capricor Therapeutics by 625.0% in the 4th quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company’s stock worth $80,000 after buying an additional 5,000 shares during the period. 21.68% of the stock is currently owned by institutional investors.

Capricor Therapeutics Price Performance

CAPR traded up $2.47 on Thursday, hitting $14.69. 2,210,259 shares of the stock were exchanged, compared to its average volume of 1,369,690. The firm has a market capitalization of $667.95 million, a price-to-earnings ratio of -13.88 and a beta of 4.10. The business has a 50-day moving average of $14.05 and a two-hundred day moving average of $14.50. Capricor Therapeutics has a 12 month low of $3.52 and a 12 month high of $23.40.

Capricor Therapeutics (NASDAQ:CAPR) last released its earnings results on Wednesday, March 19th. The biotechnology company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.15. Capricor Therapeutics had a negative return on equity of 112.95% and a negative net margin of 146.86%. The business had revenue of $11.13 million during the quarter, compared to analysts’ expectations of $9.87 million. Equities research analysts expect that Capricor Therapeutics will post -1.21 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have issued reports on CAPR shares. HC Wainwright reaffirmed a “buy” rating and issued a $77.00 price objective on shares of Capricor Therapeutics in a research report on Monday. Cantor Fitzgerald reiterated an “overweight” rating and issued a $30.00 price objective on shares of Capricor Therapeutics in a report on Thursday. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $34.50.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.